ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1109

Gene Expressions of TMEM176A and TMEM176B Were Prominent at the Stage of Subclinical Pulmonary Vascular Disease in Systemic Sclerosis

Yoshinobu Koyama1, Soichiro Fuke2, Takashi Ohno3, Yoshiharu Sato4 and Toshie Higuchi1, 1Center for Autoimmune Diseases, Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan, 2Department of Cardiology, Japan Red Cross Okayama Hospital, Okayama, Japan, 3Management of medical safety, Okayama University Hospital, Okayama, Japan, 4DNA Chip Research Inc, Tokyo, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Gene Expression, mechanisms, pathogenesis and systemic sclerosis, Pulmonary Involvement

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Session Title: Systemic Sclerosis and Related Disorders – Basic Science Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Pulmonary arterial hypertension (PAH) is prominent as a vascular involvement of systemic sclerosis (SSc), which remains a leading cause of death in spite of current best treatments. As the pulmonary vascular disease (PVD) can be well compensated for, more than a half of the pulmonary circulation is impaired before PAH is detected. So far, the underlying molecular mechanisms have not been fully elucidated, especially at the early stage of SSc.In this study, we focused on the stage of subclinical PVD, and try to detect candidate genes involved in the pathogenesis of exercise-induced pulmonary hypertension (exPH) at the early stage of SSc.

Methods: Total of 88 patients who had not met PAH criteria with Raynaud phenomenon (n=75), skin sclerosis (n=58) or SSc-related autoantibody(n=59) was enrolled. To detect the early PVD, exercise Doppler echocardiography was carried out. The exPH group was segregated from normal response group (exN) with using the reported definition.1)For gene expression analysis, total RNAs from whole peripheral blood cells were extracted by PAXgene system and multiplex sequencing was done. To identify changes of transcriptomes for developing exPH, hierarchical clustering, weighted gene co-expression network analysis (WGCNA), pathway enrichment analysis (PathVisio) and volcano plots were performed with using differentially expressed genes (DEGs) between exPH and exN group.

Results: After applying 1204 DEGs to hierarchical clustering analysis, 5 major clusters were identified and 93% of exPH samples were segregated into 2ndcluster. WGCNA and pathway analysis revealed 6 co-expression modules and they weresignificantly enriched with genes of several pathways, such as Wnt, endothelin, IL-1, TNF-alpha, prostaglandin, toll-like receptor, EGF, VEGF-A, type3 interferon and integrin-mediated cell adhesion. Volcano plots were scatter plots calculated to visualizefold-changes and p-values of DEGs. It indicated that expressions of TMEM176A and TMEM176B (log2fold-change >1.25 and –log10 p-value >3.5) were prominent in exPH patients. We also found that the expressions of these genes were highly correlated with each other (R2=0.9724, p<0.01).

Conclusion: The paradigm of SSc-PAH management should ideally be aimed at starting treatment before development of PAH. Although elucidating the mechanisms for progression of PVD in the early stage of SSc remains a major challenge, (1) we found exPH patients were segregated from exN group by gene expression profiles of peripheral blood; (2) DEGs were enriched with genes of several important pathways for pathogenesis of SSc, which reported previously; (3) up-regulation of TMEM176A and TMEM176B were prominent in exPH group. The trans-membrane protein TMEM176A and TMEM176B were found initially to be a regulator for DC maturation in mice2), but functions of human ortholog of these genes remain still unclear. As our findings revealed active changes of transcriptomes in peripheral blood prior to fulfilling PAH criteria in SSc patients, it will encourage the therapeutic intervention at early stage of SSc to prevent PVD.

References:1)R. Naeijeet al., Am J resp and critical care med187, 576-583 (2013). 2)Condamine, T.et al., J of leuko biol88, 507-515 (2010).


Disclosure: Y. Koyama, None; S. Fuke, None; T. Ohno, None; Y. Sato, None; T. Higuchi, None.

To cite this abstract in AMA style:

Koyama Y, Fuke S, Ohno T, Sato Y, Higuchi T. Gene Expressions of TMEM176A and TMEM176B Were Prominent at the Stage of Subclinical Pulmonary Vascular Disease in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/gene-expressions-of-tmem176a-and-tmem176b-were-prominent-at-the-stage-of-subclinical-pulmonary-vascular-disease-in-systemic-sclerosis/. Accessed February 6, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gene-expressions-of-tmem176a-and-tmem176b-were-prominent-at-the-stage-of-subclinical-pulmonary-vascular-disease-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences